Alpine Woods Capital Investors LLC Sells 1,715 Shares of Johnson & Johnson (NYSE:JNJ)

Alpine Woods Capital Investors LLC decreased its holdings in shares of Johnson & Johnson (NYSE:JNJ - Free Report) by 5.6% during the 1st quarter, according to the company in its most recent 13F filing with the Securities & Exchange Commission. The fund owned 29,057 shares of the company's stock after selling 1,715 shares during the quarter. Johnson & Johnson makes up about 1.2% of Alpine Woods Capital Investors LLC's holdings, making the stock its 28th biggest position. Alpine Woods Capital Investors LLC's holdings in Johnson & Johnson were worth $4,819,000 at the end of the most recent quarter.

Several other hedge funds also recently modified their holdings of the business. Ascent Capital Management LLC increased its stake in shares of Johnson & Johnson by 19.3% during the 1st quarter. Ascent Capital Management LLC now owns 1,773 shares of the company's stock worth $294,000 after purchasing an additional 287 shares during the last quarter. Leavell Investment Management Inc. increased its stake in shares of Johnson & Johnson by 5.4% during the 1st quarter. Leavell Investment Management Inc. now owns 40,364 shares of the company's stock worth $6,694,000 after purchasing an additional 2,062 shares during the last quarter. Quotient Wealth Partners LLC increased its stake in shares of Johnson & Johnson by 5.9% during the 1st quarter. Quotient Wealth Partners LLC now owns 12,811 shares of the company's stock worth $2,125,000 after purchasing an additional 714 shares during the last quarter. Main Street Research LLC increased its stake in shares of Johnson & Johnson by 20.4% during the 1st quarter. Main Street Research LLC now owns 12,806 shares of the company's stock worth $2,124,000 after purchasing an additional 2,166 shares during the last quarter. Finally, Mraz Amerine & Associates Inc. increased its stake in shares of Johnson & Johnson by 0.5% during the 1st quarter. Mraz Amerine & Associates Inc. now owns 24,242 shares of the company's stock worth $3,969,000 after purchasing an additional 124 shares during the last quarter. Institutional investors and hedge funds own 69.55% of the company's stock.

Wall Street Analysts Forecast Growth

JNJ has been the topic of a number of research analyst reports. Royal Bank Of Canada reiterated an "outperform" rating and issued a $181.00 target price on shares of Johnson & Johnson in a research note on Thursday, June 5th. Guggenheim reiterated a "neutral" rating on shares of Johnson & Johnson in a research note on Wednesday, April 2nd. Barclays lowered their target price on shares of Johnson & Johnson from $166.00 to $165.00 and set an "equal weight" rating on the stock in a research note on Thursday, April 17th. Wall Street Zen upgraded shares of Johnson & Johnson from a "buy" rating to a "strong-buy" rating in a research note on Saturday, June 21st. Finally, Leerink Partners lowered shares of Johnson & Johnson from an "outperform" rating to a "market perform" rating and lowered their target price for the company from $169.00 to $153.00 in a research note on Tuesday, May 13th. Eleven research analysts have rated the stock with a hold rating, seven have issued a buy rating and three have given a strong buy rating to the company. According to MarketBeat.com, the stock has an average rating of "Moderate Buy" and a consensus target price of $171.00.

Johnson & Johnson Price Performance

Shares of NYSE:JNJ traded down $0.82 during midday trading on Friday, reaching $156.87. 7,866,488 shares of the company's stock were exchanged, compared to its average volume of 8,066,975. The company's 50 day simple moving average is $153.73 and its two-hundred day simple moving average is $154.35. The firm has a market capitalization of $377.44 billion, a PE ratio of 17.45, a price-to-earnings-growth ratio of 2.15 and a beta of 0.41. Johnson & Johnson has a 12 month low of $140.68 and a 12 month high of $169.99. The company has a debt-to-equity ratio of 0.49, a quick ratio of 1.03 and a current ratio of 1.26.

Johnson & Johnson (NYSE:JNJ - Get Free Report) last announced its quarterly earnings results on Tuesday, April 15th. The company reported $2.77 earnings per share (EPS) for the quarter, beating the consensus estimate of $2.59 by $0.18. Johnson & Johnson had a net margin of 24.42% and a return on equity of 33.46%. The firm had revenue of $21.89 billion during the quarter, compared to the consensus estimate of $21.65 billion. Equities research analysts expect that Johnson & Johnson will post 10.58 earnings per share for the current fiscal year.

Johnson & Johnson Increases Dividend

The company also recently declared a quarterly dividend, which was paid on Tuesday, June 10th. Investors of record on Tuesday, May 27th were issued a dividend of $1.30 per share. This is an increase from Johnson & Johnson's previous quarterly dividend of $1.24. This represents a $5.20 annualized dividend and a yield of 3.31%. The ex-dividend date was Tuesday, May 27th. Johnson & Johnson's dividend payout ratio (DPR) is currently 57.84%.

Johnson & Johnson Profile

Johnson & Johnson is a holding company, which engages in the research, development, manufacture, and sale of products in the healthcare field. It operates through the Innovative Medicine and MedTech segments. The Innovative Medicine segment focuses on immunology, infectious diseases, neuroscience, oncology, cardiovascular and metabolism, and pulmonary hypertension.